Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News21 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
General11 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General21 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity
-
General17 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank